Vanguard Group Inc. Has $74.73 Million Holdings in LifeStance Health Group, Inc. $LFST

Key Points

• Vanguard Group Inc. increased its stake in LifeStance Health Group, boosting holdings by 5.0% with a total of 11,221,237 shares valued at approximately $74.7 million.
• Multiple institutional investors, including R Squared Ltd and US Bancorp DE, have significantly raised their stakes in LifeStance Health Group, contributing to a total of 85.50% institutional ownership.
• Analysts project growth for LifeStance Health Group, with UBS Group raising the target price from $8.50 to $9.00 and a general consensus rating of "Moderate Buy."

Vanguard Group Inc. grew its stake in LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 5.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 11,221,237 shares of the company's stock after purchasing an additional 531,841 shares during the quarter. Vanguard Group Inc. owned about 2.89% of LifeStance Health Group worth $74,733,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. LPL Financial LLC grew its holdings in shares of LifeStance Health Group by 6.0% in the 4th quarter. LPL Financial LLC now owns 37,584 shares of the company's stock valued at $277,000 after acquiring an additional 2,127 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of LifeStance Health Group by 36.2% in the fourth quarter. Wells Fargo & Company MN now owns 74,731 shares of the company's stock valued at $551,000 after buying an additional 19,869 shares in the last quarter. Invesco Ltd. raised its position in shares of LifeStance Health Group by 30.3% in the fourth quarter. Invesco Ltd. now owns 162,146 shares of the company's stock valued at $1,195,000 after buying an additional 37,718 shares in the last quarter. Legal & General Group Plc raised its position in shares of LifeStance Health Group by 4.6% in the fourth quarter. Legal & General Group Plc now owns 134,557 shares of the company's stock valued at $992,000 after buying an additional 5,917 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of LifeStance Health Group in the fourth quarter valued at approximately $2,623,000. Institutional investors own 85.50% of the company's stock.

Insider Activity

In related news, Director Darren M. Black sold 8,407,643 shares of the business's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $5.07, for a total value of $42,626,750.01. Following the transaction, the director owned 33,524,715 shares in the company, valued at $169,970,305.05. The trade was a 20.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Summit Partners L. P sold 8,407,643 shares of the business's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $5.07, for a total transaction of $42,626,750.01. Following the completion of the transaction, the insider owned 33,524,715 shares in the company, valued at approximately $169,970,305.05. The trade was a 20.05% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 20,423,643 shares of company stock worth $103,561,790 in the last three months. Corporate insiders own 3.20% of the company's stock.

Analyst Ratings Changes

Several research analysts have commented on the stock. UBS Group boosted their price objective on shares of LifeStance Health Group from $8.50 to $9.00 and gave the company a "buy" rating in a research report on Friday, August 8th. Wall Street Zen upgraded shares of LifeStance Health Group from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, BTIG Research assumed coverage on shares of LifeStance Health Group in a research report on Friday, July 25th. They set a "buy" rating and a $8.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $8.50.

LifeStance Health Group Trading Down 0.5%

Shares of LifeStance Health Group stock traded down $0.03 during trading on Thursday, hitting $5.47. The company's stock had a trading volume of 610,245 shares, compared to its average volume of 2,014,617. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.48 and a quick ratio of 1.48. LifeStance Health Group, Inc. has a 52 week low of $3.74 and a 52 week high of $8.61. The stock has a market cap of $2.13 billion, a price-to-earnings ratio of -109.50 and a beta of 1.13. The stock has a 50-day moving average price of $4.70 and a two-hundred day moving average price of $5.95.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.02. LifeStance Health Group had a negative net margin of 1.23% and a negative return on equity of 1.11%. The company had revenue of $345.31 million for the quarter, compared to analysts' expectations of $345.05 million. During the same quarter in the previous year, the firm posted ($0.06) earnings per share. LifeStance Health Group's revenue for the quarter was up 10.6% on a year-over-year basis. LifeStance Health Group has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts anticipate that LifeStance Health Group, Inc. will post -0.18 EPS for the current fiscal year.

LifeStance Health Group Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.